Navigation Links
BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
Date:9/22/2008


Toronto Stock Exchange Symbol: MS

- US$10 million received based on the positive review of interim

analysis for international pivotal multiple sclerosis trial -

EDMONTON, Sept. 22 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that it has received the US$10 million milestone payment from its partner, Eli Lilly and Company.

The milestone payment is based on the previously announced positive review of the scheduled interim analysis of the Company's pivotal phase II/III Canadian and European trial (MAESTRO-01) of dirucotide (MBP8298) in patients with secondary progressive MS. The independent Data Safety Monitoring Board (DSMB) for the MAESTRO-01 trial recommended that the trial proceed to completion based on the interim analysis which included efficacy and safety data from the first 200 patients to complete the trial.

To date, BioMS has received a total of US$97 million in payments from Eli Lilly and Company, based on the licensing and development agreement for dirucotide (MBP8298). An additional $400 million in milestone payments are possible under the terms of the licensing agreement, in addition to escalating royalties on sales.

"We are pleased that our partner has recognized the outcome of the interim analysis as a significant positive event," said Kevin Giese, President and CEO of BioMS Medical. "We look forward to completing the MAESTRO-01 trial and reviewing the complete data set in the second half of 2009."

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
2. BioMS Medical to present at UBS Global Life Sciences Conference
3. BioMS Medicals lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA
4. BioMS Medical announces its intention to renew a normal course issuer bid
5. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
6. BioMS Medical Announces Second Quarter 2008 Results
7. BioMS Medical completes patient recruitment in phase III U.S. multiple sclerosis trial
8. BioMS Medical to present at BMO Healthcare Conference
9. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
10. BioMS Medical to present at Jefferies Healthcare Conference
11. BioMS Medical to present at 2008 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... September 1, 2015 Shire plc (LSE: ... Sara Mathew to its Board of Directors as a ... Audit, Compliance & Risk Committee of the Shire Board. Both ... Sara previously served as Chairman, President and Chief Executive ... 2013. During her 12-year tenure at D&B, she helped drive ...
(Date:8/31/2015)... ... 31, 2015 , ... In recent years, biodegradable plastics have ... carbon footprints and compostability. These properties can help in limiting the degradation of ... of applications, the market for biodegradable plastics can be broadly segmented into packaging, ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has ... Market - Growth, Trends & Forecasts (2014-2020)" report ... Biomedical Sensors market is estimated at $0.20 billion by ... 2014-2020 The near future will bring biomedical ... each individual. These sensors can be set to trigger ...
(Date:8/31/2015)...  For people with Down syndrome, news from ... company, located in the Science + Technology Park at ... therapies yet for people with Down syndrome and other chromosome ... syndrome and Edwards syndrome aneuploidies in human cell cultures, ... Elixirgen plans to develop this technology into a treatment ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 2Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 3Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 4Biodegradable Plastics Market Growing at 10.8% CAGR to 2020 5Mexico Biomedical Sensors Market Report 2015-2020 2New Down syndrome therapy discovered 2
... The atherosclerosis vaccine,development program by AFFiRiS AG ... The respective project is being carried out in,cooperation ... of,atherosclerosis vaccination is to increase the amount of ... and thus reduce the occurrence of,harmful fatty deposits ...
... PARK, Calif., May 27 ForteBio(R), Inc., a ... development of biotherapeutic and pharmaceutical products, today announced ... - for high-sensitivity protein quantitation and fragment screening, ... instrumentation platform. The new modules are available via ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical ... ) focused on bringing the life saving ... today that it has reduced its secured debt by a ... 2009. "On April 6th, 2009, Cord Blood America announced ...
Cached Biology Technology:AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2Cord Blood America Says Debt Reduced $4.194 Million in 2009 2
(Date:8/25/2015)... BELLEVUE, Wash. , Aug. 25, 2015 /PRNewswire/ ... announced today it will unveil its "Guardian S" snake ... the National Tactical Officers Association Conference on August 30 ... S is the first-ever commercially available energetically autonomous snake ... and in-field trials and is protected by more than ...
(Date:8/24/2015)... -- Based on its recent analysis of the biometric products market, ... Company of the Year Award. DERMALOG is the leading German ... Africa . It has particularly gained prominence in ... of the largest biometric mass applications in the world, and ... of Nigeria with its biometric products. ...
(Date:8/20/2015)... Calif. , Aug. 20, 2015   ... focused on improving the user experience and security ... vision technologies, today announced that its TrulySecure™ ... biometric authentication software to be FIDO Certified™. ... TrulySecure for compliance with the FIDO UAF (Universal ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... between poor sleep and schizophrenia have found that irregular ... trigger some of the disease,s symptoms. The findings, published ... prolonged disturbances might be a cause and not just ... possible link between poor sleep and schizophrenia prompted the ...
... lead by Joris Messens (VIB / Vrije Universiteit Brussel) ... bacterium that causes tuberculosis has an ingenious defence ... search for a treatment for tuberculosis. 9.4 million people ... die as a result. Joris Messens: "We ...
... belong to the students, favourite ones. Inappropriately lectured, thermodynamics ... related to each other. A new textbook on thermodynamics, ... Chemistry of the Polish Academy of Sciences, Warsaw, transmits ... way presenting it as a field of science with ...
Cached Biology News:Could poor sleep contribute to symptoms of schizophrenia? 2'Missing link' discovered in the defence mechanism of the tuberculosis pathogen 2Thermodynamics really from scratch -- in a new textbook 2Thermodynamics really from scratch -- in a new textbook 3
... of the mitochondrial transmembrane potential ... intracellular events that occur following ... Apoptosis Detection Kit utilizes a ... as a mitochondrial activity marker. ...
The PDS-1000 He Hepta system includes the PDS-1000 He biolistic system and the Hepta adaptor....
... BioLogic LP system, 220-240 V, is ... fraction collection. The system includes the ... kit with MV-6 injection valve, proportioning ... cell, tubing and fittings kit, column ...
... been developed for affinity capture of ... of ProteinChip chemical surfaces allow differential ... unique biochemical properties. Each chip has ... comparison, and the chips are color-coded ...
Biology Products: